Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

Medicare Part D will cover popular weight loss drugs like Wegovy and Ozempic starting in 2026, with copays capped at $50 per ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

The cash price for popular weight-loss medications Wegovy and the medication authorized for people with type 2 diabetes Ozempic are dropping by 30% in the U.S. on Monday, according to Novo Nordisk, ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.